The MAGELIA project was born with the aim to fulfil the unmet needs in library preparation (DNA/RNA sample preparation) for low to medium throughput Next Generation Sequencing (NGS) analysis.
NGS is a set of powerful technologies that have enabled the reading of thousands to millions of DNA molecules simultaneously, revolutionizing fields such as personalised medicine, genetic diseases study, and clinical diagnostics. However, the upstream process to generate a collection of DNA fragments for reading, called library preparation, is still the main burden to NGS democratisation. For low-medium throughput laboratories, representing 80% of the market, NGS library preparation is currently done manually using several instruments and many manual steps like DNA amplification, pooling, normalisation, etc. This process is error-prone and leads to numerous pain-points for users such as large sample input required, low reproducibility, long hands-on-time and high cost.
At Inorevia, we believe that the solution to overcome these limitations lies in the miniaturisation and automation of library preparation by using our microfluidic technologies. To this end, we developed MAGELIA, a cutting-edge platform for low-medium throughput NGS library preparation.
MAGELIA will allow scarce-resources and small laboratories to use all NGS potential by reducing complexity and library preparation costs, increasing results’ reproducibility and freeing technicians’ time.
The H2020 SMEi2 project aims to transform a very promising platform prototype (TRL 6-7) to a fully automated, high quality and time-saving sample preparation instrument (TRL9). In parallel, all necessary actions strengthening the go-to-market strategy, communication & dissemination, and IP & FTO issues, will be implemented.
By the project ends, Inorevia achieved the full completion of the main milestones of the project, namely: the Magelia platform is ready to enter the Market, and applications have been developed to validate the potential of the platform.
The project will have a positive impact on the European biotech environment, and potentially trigger the emergence of European biotech leaders. Ultimately, through the improvement of Research and Diagnostics, it will benefit all European citizens.
